It is used with other relevant treatments in advanced squamous cell carcinoma of the head and neck, recurrent locoregional disease or metastatic squamous cell
carcinoma of the head and neck, and recurrent or metastatic squamous cell carcinoma of the head, neck progressing after platinum-based therapy, and in colorectal cancer.
400 mg/m2 initially (infused over a period of 2 hrs) then 250 mg/m2 weekly. To administer an H1 receptor antagonist prior to initiation of treatment.
Mode of action
Brands containing this Ingredient
5 mg / mL; 20 mL
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is an epidermal growth factor receptor (EGFR) antagonist
It can cause serious and fatal infusion reactions; monitor serum electrolytes such as serum magnesium, potassium, and calcium, during and post Cetuximab administration.
Allergic to any component of the formulation and pregnancy.
Headache, diarrhea, allergic reactions (manifested as rash and pruritus, among others), nail changes, pulmonary toxicity, hypomagnesemia and other electrolyte imbalances, and infections.
It can cause fetal harm when administered to a pregnant woman.